Results 91 to 100 of about 103,365 (348)

GLP-1 and Its Role in Glycogen Production: A Narrative Review

Biomedicines
Glucagon-like peptide-1 (GLP-1) has emerged as a pivotal regulator in the management of glucose homeostasis, glycogen metabolism, and energy balance, positioning it as a critical therapeutic target for addressing obesity, metabolic syndrome, and type 2 ...
Joseph Lotosky, Xavier Jean, Anungoo Altankhuyag, Saqib Khan, Ashley Bernotas, Alireza Sharafshah, Kenneth Blum, Alan Posner, Panayotis K. Thanos   +8 more
doaj   +1 more source

The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity. [PDF]

, 2017
ObjectiveThe differential effect of GLP-1 agonist Exenatide on functional connectivity of the nucleus tractus solitaries (NTS), a key region associated with homeostasis, and on appetite-related behaviours was investigated in women with normal weight ...
Connolly, L, Coveleskie, K, Gupta, A, Kilpatrick, LA, Labus, JS, Mayer, EA, Sanmiguel, C, Stains, J   +7 more
core   +3 more sources

Temporal glomerular gene expression dynamics during disease progression in a mouse model of hypertension‐accelerated diabetic kidney disease

Animal Models and Experimental Medicine, EarlyView.
The current study characterized temporal changes in glomerular gene expression, pathology, and biomarkers in a mouse model of hypertension‐accelerated diabetic kidney disease (DKD). Progressive albuminuria and glomerulosclerosis were paralleled by dynamic transcriptomic changes associated withmetabolic dysfunction, extracellular matrix remodeling, and ...
Adam B. Marstrand‐Jørgensen, Frederikke Emilie Sembach, Maria Ougaard, Ditte Hansen, Mette Viberg Østergaard, Henrik H. Hansen, Louise S. Dalbøge, Ole Jørgen Kaasbøll, Michael Christensen   +8 more
wiley   +1 more source

Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling [PDF]

, 2013
It has been estimated that approximately 8.4% of the world population currently live with diabetes mellitus and type 2 diabetes is the most common form. Type 2 diabetes increases the risk of complications such as heart attacks, blindness, amputations and
Venkat Kanamarlapudi
core   +1 more source

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, EarlyView.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source

The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]

, 2013
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core   +2 more sources

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

Arthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli, Diane Lacaille, Na Lu, Hui Xie, J. Antonio Aviña‐Zubieta   +4 more
wiley   +1 more source

Decision letter for "Cardiovascular risk profiles: A cross‐sectional study evaluating the generalisability of the glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials Rewind , Leader and Sustain ‐6 to the real‐world type 2 diabetes population in the UK"

, 2021

openalex   +1 more source

Glucagon receptor family (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database [PDF]

, 2019
The glucagon family of receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on the Glucagon receptor family [159]) are activated by the endogenous peptide (27-44 aa) hormones glucagon, glucagon-like peptide 1, glucagon-like peptide 2, glucose ...
Bataille, Dominique, Chan, Susan L., Delagrange, Philippe, Drucker, Daniel J., Göke, Burkhard, Hills, Rebecca, Mayo, Kelly E., Miller, Laurence J., Salvatori, Roberto, Thorens, Bernard   +9 more
core   +2 more sources

Beyond right or wrong: How partial credit scoring on multiple‐choice questions improves student performance and assessment perceptions

British Journal of Clinical Pharmacology, EarlyView.
Aims In this study, we examined the effects of assigning partial credit to selected answer choices on student performance and perceptions in a pharmacology course using Type A multiple‐choice questions (MCQs). Methods Partial credit scoring was incorporated into quizzes and exams in a 10‐week pharmacology course for postbaccalaureate premedical ...
Stephen D. Schneid, Chris Armour, Katharina Brandl   +2 more
wiley   +1 more source